These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
774 related articles for article (PubMed ID: 17178259)
1. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Neuvonen PJ; Niemi M; Backman JT Clin Pharmacol Ther; 2006 Dec; 80(6):565-81. PubMed ID: 17178259 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin. Neuvonen PJ; Backman JT; Niemi M Clin Pharmacokinet; 2008; 47(7):463-74. PubMed ID: 18563955 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Williams D; Feely J Clin Pharmacokinet; 2002; 41(5):343-70. PubMed ID: 12036392 [TBL] [Abstract][Full Text] [Related]
4. Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics. Neuvonen PJ Curr Opin Investig Drugs; 2010 Mar; 11(3):323-32. PubMed ID: 20178046 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Shitara Y; Sugiyama Y Pharmacol Ther; 2006 Oct; 112(1):71-105. PubMed ID: 16714062 [TBL] [Abstract][Full Text] [Related]
6. Drug-drug interactions that interfere with statin metabolism. Hirota T; Ieiri I Expert Opin Drug Metab Toxicol; 2015; 11(9):1435-47. PubMed ID: 26058399 [TBL] [Abstract][Full Text] [Related]
7. Analysis of the repaglinide concentration increase produced by gemfibrozil and itraconazole based on the inhibition of the hepatic uptake transporter and metabolic enzymes. Kudo T; Hisaka A; Sugiyama Y; Ito K Drug Metab Dispos; 2013 Feb; 41(2):362-71. PubMed ID: 23139378 [TBL] [Abstract][Full Text] [Related]
8. Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Cohen LH; van Leeuwen RE; van Thiel GC; van Pelt JF; Yap SH Biopharm Drug Dispos; 2000 Dec; 21(9):353-64. PubMed ID: 11523064 [TBL] [Abstract][Full Text] [Related]
9. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. Shitara Y; Hirano M; Sato H; Sugiyama Y J Pharmacol Exp Ther; 2004 Oct; 311(1):228-36. PubMed ID: 15194707 [TBL] [Abstract][Full Text] [Related]
10. HMG-CoA Reductase Inhibitors (Statins) and their Drug Interactions Involving CYP Enzymes, P-glycoprotein and OATP Transporters-An Overview. Balasubramanian R; Maideen NMP Curr Drug Metab; 2021; 22(5):328-341. PubMed ID: 33459228 [TBL] [Abstract][Full Text] [Related]
12. Risk of adverse events among older adults following co-prescription of clarithromycin and statins not metabolized by cytochrome P450 3A4. Li DQ; Kim R; McArthur E; Fleet JL; Bailey DG; Juurlink D; Shariff SZ; Gomes T; Mamdani M; Gandhi S; Dixon S; Garg AX CMAJ; 2015 Feb; 187(3):174-180. PubMed ID: 25534598 [TBL] [Abstract][Full Text] [Related]
13. Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport. Sakaeda T; Fujino H; Komoto C; Kakumoto M; Jin JS; Iwaki K; Nishiguchi K; Nakamura T; Okamura N; Okumura K Pharm Res; 2006 Mar; 23(3):506-12. PubMed ID: 16388406 [TBL] [Abstract][Full Text] [Related]
14. Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations. Prueksaritanont T; Ma B; Tang C; Meng Y; Assang C; Lu P; Reider PJ; Lin JH; Baillie TA Br J Clin Pharmacol; 1999 Mar; 47(3):291-8. PubMed ID: 10215754 [TBL] [Abstract][Full Text] [Related]
15. Cyclosporine markedly raises the plasma concentrations of repaglinide. Kajosaari LI; Niemi M; Neuvonen M; Laitila J; Neuvonen PJ; Backman JT Clin Pharmacol Ther; 2005 Oct; 78(4):388-99. PubMed ID: 16198658 [TBL] [Abstract][Full Text] [Related]
16. [Incremental effect and mechanism of cyclosporine on blood concentration of statins and statin package insert information in Japan]. Hirata-Koizumi M; Saito M; Miyake S; Hasegawa R Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2005; (123):37-40. PubMed ID: 16541750 [TBL] [Abstract][Full Text] [Related]
17. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Corsini A; Bellosta S; Baetta R; Fumagalli R; Paoletti R; Bernini F Pharmacol Ther; 1999 Dec; 84(3):413-28. PubMed ID: 10665838 [TBL] [Abstract][Full Text] [Related]
18. Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus. Lemahieu WP; Hermann M; Asberg A; Verbeke K; Holdaas H; Vanrenterghem Y; Maes BD Am J Transplant; 2005 Sep; 5(9):2236-43. PubMed ID: 16095503 [TBL] [Abstract][Full Text] [Related]
19. Downregulation of Organic Anion Transporting Polypeptide (OATP) 1B1 Transport Function by Lysosomotropic Drug Chloroquine: Implication in OATP-Mediated Drug-Drug Interactions. Alam K; Pahwa S; Wang X; Zhang P; Ding K; Abuznait AH; Li L; Yue W Mol Pharm; 2016 Mar; 13(3):839-51. PubMed ID: 26750564 [TBL] [Abstract][Full Text] [Related]
20. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Jacobson TA Am J Cardiol; 2004 Nov; 94(9):1140-6. PubMed ID: 15518608 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]